Ozero (Etoricoxib 60, 90, 120 mg)

Product Description

Ozero as Etoricoxib is a selective nonsteroidal anti-inflammatory drug (NSAID) used primarily for the management of pain and inflammation associated with various conditions, including osteoarthritis, rheumatoid arthritis, and acute gouty arthritis. By specifically inhibiting the cyclooxygenase-2 (COX-2) enzyme, etoricoxib effectively reduces pain and swelling while minimizing gastrointestinal side effects commonly associated with traditional NSAIDs.

Pharco International Company

  • SA
  • 2024
    On CPHI since
  • 2
    Certificates
  • 25 - 49
    Employees
Company types
Pharmaceutical company
Primary activities
Pharmaceutical Company (generic finished products)
Specifications
  • Details
    Ozero contains Etoricoxib 120 mg, 60 mg and 90 mg as selective COX-2 Inhibitor
  • Selling Points
    Bone & Joint Health; Product Features; Key Benefits:
    • Targeted Pain Relief: Ozero as Etoricoxib provides effective relief from moderate to severe pain, making it suitable for managing conditions such as osteoarthritis and rheumatoid arthritis.
    • Reduced Gastrointestinal Risk: Unlike traditional NSAIDs that inhibit both COX-1 and COX-2 enzymes, Ozero as etoricoxib's selective action helps to lower the risk of gastrointestinal complications, such as ulcers and bleeding.
    • Convenient Dosing: Available in various strengths, Ozero as etoricoxib can be administered once daily, enhancing patient compliance and convenience.
    • Rapid Onset of Action: Patients often experience relief from pain and inflammation relatively quickly, improving their quality of life
    Etoricoxib is typic...
  • Supplied from
    Saudi Arabia
  • Measured In
    milligram

Pharco International Company

  • SA
  • 2024
    On CPHI since
  • 2
    Certificates
  • 25 - 49
    Employees
Company types
Pharmaceutical company
Primary activities
Pharmaceutical Company (generic finished products)

More Products from Pharco International Company (6)

  • Farcolin respirator solution

    Product Farcolin respirator solution

    Farcolin Respirator Solution (Salbutamol) is indicated for the treatment and management of bronchospasm in conditions such as asthma and chronic obstructive pulmonary disease (COPD). It provides quick relief from wheezing, shortness of breath, and other respiratory symptoms associated with these conditions.
  • Milora HCT

    Product Milora HCT

    Milora HCT (Amlodipine/valsartan/hydrochlorothiazide) is a combination medication used to treat high blood pressure (hypertension).
    The product is available in 4 SKUs (Aml/Val/HCT: 5/160/12.5, 10/160/12.5, 5/160/25, 10/160/25)
    Amlodipine is a calcium channel blocker that relaxes blood vessels, impr...
  • Neurovit tab

    Product Neurovit tab

    Neurovit Tablets are B Complex tablets designed to support nerve health and enhance cognitive function. Each tablet is formulated with high-potency B vitamins, including:

    • Vitamin B1 (Thiamine) - 250 mg: Essential for energy metabolism and proper nerve function, thiamine plays a crucial ...
  • Paracetamol IV infusion

    Product Paracetamol IV infusion

    Paracetamol IV infusion is indicated for the management of mild to moderate pain and for the reduction of fever in patients who are unable to take oral medication. It is commonly used in postoperative settings, for patients with severe nausea or vomiting, and in those requiring pain management in a hospita...
  • Ticanase nasal spray

    Product Ticanase nasal spray

    Ticanase Nasal Spray is indicated for the management of nasal symptoms associated with allergic rhinitis (hay fever) and other inflammatory nasal conditions. It effectively reduces nasal congestion, sneezing, and runny nose.
  • Vertex

    Product Vertex

    Vertex as Rosuvastatin is a powerful statin medication used to lower cholesterol levels and reduce the risk of cardiovascular disease. As an HMG-CoA reductase inhibitor, it works by blocking a key enzyme involved in cholesterol production in the liver.

Pharco International Company resources (3)

  • News Pharco is leading the Egyptian market with 7.8% share (IQVIA MAT Mar 2024)

    Pharco Pharmaceuticals has established itself as a leader in the Egyptian pharmaceutical market, holding a 7.8% market share. This significant position reflects the company’s commitment to providing high-quality medications across various therapeutic areas. Pharco's success is driven by its extensive product portfolio, innovative manufacturing practices, and dedication to meeting the healthcare needs of the community. As a key player in the industry, Pharco continues to enhance its presence and influence within the Egyptian healthcare sector.
  • Technical Data Pharco Product List

    Pharco Pharmaceuticals is a leading manufacturer of high-quality pharmaceuticals, offering a diverse range of products across various therapeutic categories. Our comprehensive portfolio includes:
    Prescription Medications: Covering a wide array of therapeutic areas, including cardiology, oncology, and infectious diseases.
    Over-the-Counter (OTC) Products: A selection of non-prescription medications designed to address common health concerns.
    Biologics and Biosimilars: Innovative treatments that leverage biological processes to provide effective solutions for complex medical conditions.
    Generic Medications: Affordable alternatives to branded drugs, ensuring accessibility for patients without compromising quality.
    Dosage Forms: Available in multiple forms, including tablets, capsules, injectables, and topical formulations, to meet diverse patient needs
  • News Forbes' Top 100 Healthcare Leaders in the Middle East!, Dr. Sherine Helmy, CEO of Pharco Pharmaceuticals

    Dr. Sherine Helmy, CEO of Pharco Pharmaceuticals, has been named one of Forbes' Top 100 Healthcare Leaders in the Middle East. This recognition highlights her exceptional leadership and commitment to improving healthcare access in the region. Under her guidance, Pharco has expanded its product portfolio and established advanced manufacturing facilities, reinforcing its position in the pharmaceutical industry. Dr. Helmy's innovative strategies and advocacy for health initiatives have significantly enhanced patient outcomes. This accolade underscores her impactful contributions to the healthcare sector and her dedication to fostering a healthier future. Congratulations to Dr. Helmy on this prestigious honor!